This global market research report includes a detailed segmentation of the idiopathic pulmonary fibrosis market by route of administration (oral and parenteral) and by drug class (systemic corticosteroids, immunosuppressant drugs, tyrosine kinase inhibitors, and anti-fibrotic agents). It also outlines the market shares for key regions like the Americas, APAC, and EMEA. The top vendors analyzed in this report are Baxter, Boehringer Ingelheim, F. Hoffmann-La Roche, and Prometheus.
Technavio’s market research analysts estimate the global idiopathic pulmonary fibrosis market to grow at a high CAGR of almost 24% between 2016 and 2020. Special regulatory designations such as orphan and fast track designations for molecules under development provided for pipeline candidates by regulatory authorities is the primary driver for this market. Also, the growth in patient population plays a vital role in the growth of the market. At present, the Americas dominate the global idiopathic pulmonary fibrosis market, accounting for almost 44% of the overall market share. The fast drug approval process in this region is expected to propel the market in this region during the forecast period.
The new market research report from Technavio presents a breakdown and analysis of idiopathic pulmonary fibrosis segments by drug class.
“The increasing awareness of idiopathic pulmonary fibrosis and its treatment options is resulting in the increased use of the drugs for its treatment. The increase in awareness is brought on by initiatives taken by various organizations such as Pulmonary Fibrosis Foundation, which celebrate September as the Global Pulmonary Fibrosis Awareness Month. For instance, the National Organization for Rare Disorders (NORD) along with the Rare Disease Europe (EURORDIS) co-sponsors Rare Disease Day on the last day of February,” says Barath Palada, Lead Analyst, Pharma, Technavio Research.
Systemic corticosteroids and immunosuppressants are used for the treatment of idiopathic pulmonary fibrosis across the globe. During the forecast period, tyrosine kinase inhibitors such as nintedanib and anti-fibrotic agents such as pirfenidone are expected to dominate the global idiopathic pulmonary fibrosis market.
The key vendors in the global idiopathic pulmonary fibrosis market include Baxter, Boehringer Ingelheim, F. Hoffmann-La Roche, and Prometheus. The global idiopathic pulmonary fibrosis market is highly fragmented as it contains numerous multinational and local vendors. The providers in this market compete on the basis of price, quality, safety, and efficacy of the drugs to gain maximum market shares during the predicted period.
A more detailed analysis is available on the Technavio report, Global Idiopathic Pulmonary Fibrosis Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
